Application of mesenchymal stem cells and their secreted exosomes in the treatment of COVID-19
UAB Innovita Research has implemented the project “Application of mesenchymal stem cells and their secreted exosomes for the treatment of COVID-19”, co-financed by the European Regional Development Fund, provided under 2014-2020. Measure No. 1 of the European Union Funds Investment Operational Program Priority 1 “Promotion of Research, Experimental Development and Innovation” 01.2.1-LVPA-T-858 “COVID-19 R&D”. Funded as part of the European Union’s response to the COVID-19 pandemic.
The aim of the project is to carry out R&D research aimed at making COVID-19 more efficient.
During the project, it is planned to develop advanced therapy medicinal products for COVID-19 in mesenchymal stem cells (MCL) and MKL exosomes for the control of the uncontrolled inadequate immune response to COVID-19 (“cytokine storms”).
The total value of the project: EUR 799,226.31